Bank of America (BAC)

These energy stocks are surging amid skyrocketing power demand and ongoing geopolitical conflicts that have disrupted oil and gas markets.

Executives from J.B. Hunt Transport Services (NASDAQ:JBHT) said freight-market conditions are tightening, but they attributed much of the shift to capacity leaving the market rather than a broad-based demand rebound. Speaking at a Bank of America transportation conference, Brad Hicks, executive vic

Ripple is promising, but nuclear stocks could be a better bargain.

With credit conditions potentially worsening in the second half of the year, look for a flight to safety.

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended

Nuclear energy could grow into a $10 trillion industry in the next 25 years. For investors who are bullish on nuclear, these two stocks are absolute buys.

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare Conf

Integra LifeSciences (NASDAQ:IART) is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief executive officer, Chief Financial Officer Lea Knight said during a Bank of America med tech conference discussion hosted by analyst Rei Tan.

Henry Schein (NASDAQ:HSIC) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season. Speaking at a Bank of America h

GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event. Aaron said t

Shares of Citigroup have risen by more than 60% over the past year, trouncing the performance of many peers.

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

GE HealthCare Technologies (NASDAQ:GEHC) executives said the company remains confident in its long-term growth prospects despite a disappointing first quarter that led to a reduction in full-year guidance, citing inflationary cost pressures as the primary near-term challenge. Speaking at a Bank of

Nvidia is well-positioned to continue shaping the future of artificial intelligence.

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic m

Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session. Jonathan Lim, Erasca’s chair

Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and Chief Financial Officer Alexander Schuth said at a Bank of America Securities conference. Speaking

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

Akamai stock is soaring as Bank of America says the company is rapidly emerging as a major AI infrastructure player, boosting its price target to $175.

Bank of America is one of Warren Buffett's favorite stocks.

This bearish inflation report could rain on the parade when it's just getting restarted.

CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth quarter, while reiterating expectations for top-line data from a separate Phase

CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium. Speak